Literature DB >> 28905186

Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes.

Takafumi Horishita1, Nobuyuki Yanagihara2, Susumu Ueno3, Dan Okura4, Reiko Horishita4, Tomoko Minami4, Yuichi Ogata4, Yuka Sudo5, Yasuhito Uezono6, Takeyoshi Sata4, Takashi Kawasaki4.   

Abstract

Tricyclic antidepressants (TCAs) and duloxetine are used to treat neuropathic pain. However, the mechanisms underlying their analgesic effects remain unclear. Although many investigators have shown inhibitory effects of antidepressants on voltage-gated sodium channels (Nav) as a possible mechanism of analgesia, to our knowledge, no one has compared effects on the diverse variety of sodium channel α subunits. We investigated the effects of antidepressants on sodium currents in Xenopus oocytes expressing Nav1.2, Nav1.3, Nav1.6, Nav1.7, and Nav1.8 with a β1 subunit by using whole-cell, two-electrode, voltage clamp techniques. We also studied the role of the β3 subunit on the effect of antidepressants on Nav1.3. All antidepressants inhibited sodium currents in an inactivated state induced by all five α subunits with β1. The inhibitory effects were more potent for Nav1.3, Nav1.7, and Nav1.8, which are distributed in dorsal root ganglia, than Nav1.2 and Nav1.6, which are distributed primarily in the central nervous system. The effect of amitriptyline on Nav1.7 with β1 was most potent with a half-maximal inhibitory concentration (IC50) 4.6 μmol/L. IC50 for amitriptyline on Nav1.3 coexpressed with β1 was lowered from 8.4 to 4.5 μmol/L by coexpression with β3. Antidepressants predominantly inhibited the sodium channels expressed in dorsal root ganglia, and amitriptyline has the most potent inhibitory effect. This is the first evidence, to our knowledge, showing the diverse effects of antidepressants on various α subunits. Moreover, the β3 subunit appears important for inhibition of Nav1.3. These findings may aid better understanding of the mechanisms underlying the pain relieving effects of antidepressants.

Entities:  

Keywords:  Dorsal root ganglion; Duloxetine; Tricyclic antidepressants; Voltage-gated sodium channels

Mesh:

Substances:

Year:  2017        PMID: 28905186     DOI: 10.1007/s00210-017-1424-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

1.  TREATMENT OF CHRONIC TENSION HEADACHE.

Authors:  J W LANCE; D A CURRAN
Journal:  Lancet       Date:  1964-06-06       Impact factor: 79.321

Review 2.  International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.

Authors:  William A Catterall; Alan L Goldin; Stephen G Waxman
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

3.  Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels.

Authors:  Ya-Chin Yang; Chen-Syuan Huang; Chung-Chin Kuo
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

4.  Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents.

Authors:  D C Yeomans; S R Levinson; M C Peters; A G Koszowski; A Z Tzabazis; W F Gilly; S P Wilson
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

Review 5.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

Review 6.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial.

Authors:  Mary E Lynch; Alexander J Clark; Jana Sawynok; Michael J L Sullivan
Journal:  Anesthesiology       Date:  2005-07       Impact factor: 7.892

8.  Human brain fluoxetine concentrations.

Authors:  C N Karson; J E Newton; R Livingston; J B Jolly; T B Cooper; J Sprigg; R A Komoroski
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

9.  Differential blockade of neuronal voltage-gated Na(+) and K(+) channels by antidepressant drugs.

Authors:  Graham M Nicholson; Tim Blanche; Kylie Mansfield; Yvonne Tran
Journal:  Eur J Pharmacol       Date:  2002-09-27       Impact factor: 4.432

10.  Topical amitriptyline in healthy volunteers.

Authors:  Peter Gerner; Grace Kao; Venkatesh Srinivasa; Sanjeet Narang; Ging Kuo Wang
Journal:  Reg Anesth Pain Med       Date:  2003 Jul-Aug       Impact factor: 6.288

View more
  3 in total

Review 1.  Structure and Function of Sodium Channel Nav1.3 in Neurological Disorders.

Authors:  Sheng Liao; Tao Liu; Ruozhu Yang; Weitong Tan; Jiaqi Gu; Meichun Deng
Journal:  Cell Mol Neurobiol       Date:  2022-03-24       Impact factor: 5.046

2.  Sodium Channel Blockers Modulate Abnormal Activity of Regenerating Nociceptive Corneal Nerves After Surgical Lesion.

Authors:  Carolina Luna; Kamila Mizerska; Susana Quirce; Carlos Belmonte; Juana Gallar; María Del Carmen Acosta; Víctor Meseguer
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

3.  Structural basis for high-voltage activation and subtype-specific inhibition of human Nav1.8.

Authors:  Xiaoshuang Huang; Xueqin Jin; Gaoxingyu Huang; Jian Huang; Tong Wu; Zhangqiang Li; Jiaofeng Chen; Fang Kong; Xiaojing Pan; Nieng Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-19       Impact factor: 12.779

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.